Vertex Pharmaceuticals
VRTX
971 hedge funds and large institutions have $57B invested in Vertex Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 161 funds opening new positions, 388 increasing their positions, 315 reducing their positions, and 129 closing their positions.
25% more first-time investments, than exits
New positions opened: 161 | Existing positions closed: 129
23% more repeat investments, than reductions
Existing positions increased: 388 | Existing positions reduced: 315
2% more funds holding
Funds holding: 951 → 971 (+20)
1.15% less ownership
Funds ownership: 93.18% → 92.03% (-1.1%)
14% less capital invested
Capital invested by funds: $66B → $57B (-$9.01B)
25% less funds holding in top 10
Funds holding in top 10: 20 → 15 (-5)
25% less call options, than puts
Call options by funds: $276M | Put options by funds: $370M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$693M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$520M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$308M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$275M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$168M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.6B |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$392M |
| 3 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$377M |
| 4 |
Renaissance Technologies
New York
|
-$374M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
-$340M |
VRTX Hedge Fund Activity: Q4 2020 in Review
971 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2020, worth a combined $57B — down 14% from $66B a quarter earlier.
Buyers outnumbered sellers: 161 funds opened new VRTX positions and 129 closed out — a net gain of 32 holders — while 388 added to existing stakes and 315 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $693M. The largest seller was Fidelity Investments, cutting an estimated $1.6B.
- 971 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2020, up from 951 in Q3 2020.
- Funds reported $57B of Vertex Pharmaceuticals stock for Q4 2020, down 14% quarter-over-quarter.
- 161 funds opened new Vertex Pharmaceuticals positions in Q4 2020 and 129 closed out, a net change of +32 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2020 was Wellington Management Group, an estimated $693M added.
- The largest Vertex Pharmaceuticals seller in Q4 2020 was Fidelity Investments, an estimated $1.6B sold.
Based on aggregated 13F filings for Q4 2020.